These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6108361)

  • 41. Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration.
    Abernethy DR; Arendt RM; Greenblatt DJ
    Am Heart J; 1985 May; 109(5 Pt 2):1120-5. PubMed ID: 2859774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beta blockers may induce in C57BL/6 mice a polyclonal activation of lymphocytes which is not mediated by beta adrenergic receptors.
    In S; Dueymes M; Fournié GJ
    Int J Immunopharmacol; 1988; 10(7):901-6. PubMed ID: 2906911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro.
    Seifert T; Zschörnig O; Arnhold J; Arnold K
    Chem Phys Lipids; 1997 Jan; 85(1):13-21. PubMed ID: 9032944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toxicity of beta-blockers in a rat whole embryo culture: concentration-response relationships and tissue concentrations.
    Klug S; Thiel R; Schwabe R; Merker HJ; Neubert D
    Arch Toxicol; 1994; 68(6):375-84. PubMed ID: 7916561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereoselective binding of beta-blockers to purified rat alpha 1-acid glycoprotein.
    Murai-Kushiya M; Okada S; Kimura T; Hasegawa R
    J Pharm Pharmacol; 1993 Mar; 45(3):225-8. PubMed ID: 8097783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of thioproline on disturbances of action potentials of the papillary muscles caused by a large dose of lidocaine].
    Yang XM; Li XG; Zhao DH; Sheng BH
    Zhongguo Yao Li Xue Bao; 1986 Nov; 7(6):553-6. PubMed ID: 2955647
    [No Abstract]   [Full Text] [Related]  

  • 48. [Comparative study of acebutolol and pindolol in computerized electroencephalography. Trial for demonstrating central effects].
    Péchadre JC; Beudin P; Kantelip JP; Trolèse F; Moncharmont L
    Therapie; 1986; 41(6):437-41. PubMed ID: 3810540
    [No Abstract]   [Full Text] [Related]  

  • 49. [Is it possible to predict the antihypertensive action of a beta-blocker by an anti-angiotensin?].
    Lardoux H; Kreft C; Corvol P; Ménard J; Milliez P
    Nouv Presse Med; 1978 Sep; 7(31):2775. PubMed ID: 30962
    [No Abstract]   [Full Text] [Related]  

  • 50. The interference of acebutolol administration in the measurement of urinary 17-ketosteroid by Zimmermann's method.
    Ooiwa H; Shimamoto K; Nakagawa M; Iimura O
    Endocrinol Jpn; 1988 Jun; 35(3):485-90. PubMed ID: 3197660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum phosphate increase during short-term beta-adrenoceptor blockade in thyrotoxicosis.
    Kayser L; Perrild H; Fogh-Andersen N; Mølholm Hansen JE
    Acta Med Scand; 1987; 222(2):143-6. PubMed ID: 2890269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative study of acebutolol and oxprenolol in the management of hypertensive cerebrovascular diseases (CVD) patients.
    Ranakusuma TA; Samino ; Tobing SM; Almatsier M; Suyawan ; Soemargo S
    Ann Acad Med Singap; 1981 Oct; 10(4 Suppl):15-20. PubMed ID: 7344596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Assay of 17-ketosteroids in patients treated with beta-blockers].
    Reumont G; Houdent C; Kuhn JM; Gray H; Wolf LM
    Nouv Presse Med; 1979 Nov; 8(46):3832, 3835. PubMed ID: 42880
    [No Abstract]   [Full Text] [Related]  

  • 54. Time-independent effects on cardiac action potential upstroke velocity (resting block) and lipid solubility of beta adrenergic blockers.
    Sada H; Ban T
    Experientia; 1981 Feb; 37(2):171-2. PubMed ID: 6113159
    [No Abstract]   [Full Text] [Related]  

  • 55. [Central effects of five beta-adrenergic receptor blockers in healthy volunteers: a quantitative EEG study].
    Sabot C; Pechadre JC; Beudin P; Lauxerois M; Trolese JF; Kantelip JP; Ducher JL; Gibert J
    Neurophysiol Clin; 1989 Mar; 19(1):55-64. PubMed ID: 2566112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The surface activity and self-association of some beta-adrenoceptor blocking agents in aqueous solution.
    Attwood D; Agarwal SP
    J Pharm Pharmacol; 1979 Jun; 31(6):392-5. PubMed ID: 39139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Central effects of the beta-adrenergic blocking agent acebutolol. A quantitative EEG study using normalised slope descriptors.
    Kayed K; Godtlibsen OB
    Eur J Clin Pharmacol; 1977 Dec; 12(5):327-31. PubMed ID: 598404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis of 4'- and 5'-hydroxyoxprenolol:pharmacologically active ring-hydroxylated metabolites of oxprenolol.
    Burke TR; Nelson WL; Buckner CK
    J Med Chem; 1979 Dec; 22(12):1535-7. PubMed ID: 536997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New drugs: beta blockers and sympathomimetics.
    Kaye CM
    Br Med J (Clin Res Ed); 1983 Apr; 286(6375):1439. PubMed ID: 6404493
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of beta-adrenoceptor antagonists on Ca(2+)-overload induced by lysophosphatidylcholine in rat isolated cardiomyocytes.
    Chen M; Hashizume H; Abiko Y
    Br J Pharmacol; 1996 Jun; 118(4):865-70. PubMed ID: 8799555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.